These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25757469)

  • 1. Evidence-based strategies to reduce intravenous immunoglobulin-induced headaches.
    Thornby KA; Henneman A; Brown DA
    Ann Pharmacother; 2015 Jun; 49(6):715-26. PubMed ID: 25757469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency.
    Geng B; Clark K; Evangelista M; Wolford E
    Front Immunol; 2022; 13():1075527. PubMed ID: 36818468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IVIg-induced headache: prospective study of a large cohort with neurological disorders.
    Hasırcı Bayır BR; Ünsal MA; Ağırcan C; Cerrahoğlu Şirin T; Akan O; Gürsoy G; Eyigürbüz T; Mermi Dibek D; Akdağ G; Elmalı AD; Nazlı E; Akkoyun Arıkan F; Alpaydın Baslo S; Ağırcan D; Oguz-Akarsu E; Ertürk Çetin Ö; Gesoğlu Demir T; Acıman Demirel E; Vurallı D; Deveci Ş; Tanyel T; Mayda Domaç F; Karlı N; Velioğlu S; Baykan B;
    Neurol Sci; 2023 Aug; 44(8):2871-2881. PubMed ID: 36905450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy.
    Gerstenblith MR; Antony AK; Junkins-Hopkins JM; Abuav R
    J Am Acad Dermatol; 2012 Feb; 66(2):312-6. PubMed ID: 21601310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memantine for the prevention of primary headache disorders.
    Huang L; Bocek M; Jordan JK; Sheehan AH
    Ann Pharmacother; 2014 Nov; 48(11):1507-11. PubMed ID: 25159002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases.
    Graf J; Ingwersen J; Lepka K; Albrecht P; Hartung HP; Ringelstein M; Aktas O
    Acta Neurol Scand; 2019 Oct; 140(4):290-295. PubMed ID: 31269227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for diagnosing and managing medication-induced headache.
    Edmeads JG; Gawel MJ; Vickers J
    Can Fam Physician; 1997 Jul; 43():1249-54. PubMed ID: 9241463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Not all intravenous immunoglobulin preparations are equally well tolerated.
    Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF
    Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
    Gürcan HM; Ahmed AR
    Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of headache related to intravenous immunoglobulin with antimigraine medications.
    Finkel AG; Howard JF; Mann JD
    Headache; 1998 Apr; 38(4):317-21. PubMed ID: 9595875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case of IVIG-Induced Aseptic Chemical Meningitis.
    Patel A; Potu KC; Sturm T
    S D Med; 2017 Mar; 70(3):119-121. PubMed ID: 28813773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants.
    Ohlsson A; Lacy JB
    Cochrane Database Syst Rev; 2001; (2):CD000361. PubMed ID: 11405962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Special considerations with the use of intravenous immunoglobulin in older persons.
    Cheng MJ; Christmas C
    Drugs Aging; 2011 Sep; 28(9):729-36. PubMed ID: 21913738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants.
    Ohlsson A; Lacy JB
    Cochrane Database Syst Rev; 2004; (1):CD000361. PubMed ID: 14973955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
    Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
    Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Headache and Nausea after Treatment with High-Dose Subcutaneous versus Intravenous Immunoglobulin.
    Markvardsen LH; Christiansen I; Andersen H; Jakobsen J
    Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):409-12. PubMed ID: 26096187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin in autoimmune neuromuscular diseases.
    Dalakas MC
    JAMA; 2004 May; 291(19):2367-75. PubMed ID: 15150209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral transmucosal fentanyl citrate for the treatment of migraine headache pain in outpatients: a case series.
    Landy SH
    Headache; 2004 Sep; 44(8):762-6. PubMed ID: 15330821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement.
    Ibis IBP; Erdur B; Erdem SB; Karaman S; Gulez N; Genel F
    Allergol Immunopathol (Madr); 2020; 48(6):738-744. PubMed ID: 32703652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergent management of primary headache: a review of current literature.
    Naeem F; Schramm C; Friedman BW
    Curr Opin Neurol; 2018 Jun; 31(3):286-290. PubMed ID: 29461426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.